EGFR and colorectal carcinoma: All of the HER2 amplifications identified were exclusive with KRAS, NRAS and BRAF. In CRC, HER2 amplifications induced the activation of downstream signaling even when cetuximab was bound to EGFR, thus leading to drug resistance [26].